As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
13 Analysts have issued a Xvivo Perfusion forecast:
13 Analysts have issued a Xvivo Perfusion forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 814 814 |
8%
8%
|
|
| Gross Profit | 611 611 |
9%
9%
|
|
| EBITDA | 115 115 |
12%
12%
|
|
| EBIT (Operating Income) EBIT | 67 67 |
18%
18%
|
|
| Net Profit | 30 30 |
85%
85%
|
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Moelndal, Vastra Gotalands and currently employs 193 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
| Head office | Sweden |
| CEO | Mr. Rosenblad |
| Employees | 193 |
| Website | www.xvivogroup.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


